Dustin Z DeYoung1, Keith G Heinzerling, Aimee-Noelle Swanson, John Tsuang, Benjamin A Furst, Yi Yi, Ying Nian Wu, David E Moody, David M Andrenyak, Steven J Shoptaw. 1. From the *Center for Behavioral and Addiction Medicine, Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles; †Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford; ‡Department of Psychiatry, Harbor-UCLA Medical Center, Torrance; §Department of Statistics, University of California, Los Angeles, CA; and ∥Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT.
Abstract
BACKGROUND:Methamphetamine dependence is a significant public health concern without any approved medications for treatment. We evaluated ibudilast, a nonselective phosphodiesterase inhibitor, to assess the safety and tolerability during intravenous methamphetamine administration. We conducted a randomized, double-blind, placebo-controlled, within-subjects crossover clinical trial. METHODS: Participants received ibudilast (20 mg twice daily followed by 50 mg twice daily) and placebo, with order determined by randomization, and then underwent intravenous methamphetamine challenges (15 and 30 mg). We monitored cardiovascular effects, methamphetamine pharmacokinetics, and reported adverse events. RESULTS: Ibudilast treatment had similar rates of adverse events compared with placebo, and there was no significant augmentation of cardiovascular effects of methamphetamine. Pharmacokinetic analysis revealed no clinically significant change in maximum concentration or half-life of methamphetamine with ibudilast. CONCLUSIONS:Methamphetamine administration during ibudilast treatment was well tolerated without additive cardiovascular effects or serious adverse events, providing initial safety data to pursue ibudilast's effectiveness for the treatment of methamphetamine dependence.
RCT Entities:
BACKGROUND:Methamphetamine dependence is a significant public health concern without any approved medications for treatment. We evaluated ibudilast, a nonselective phosphodiesterase inhibitor, to assess the safety and tolerability during intravenous methamphetamine administration. We conducted a randomized, double-blind, placebo-controlled, within-subjects crossover clinical trial. METHODS:Participants received ibudilast (20 mg twice daily followed by 50 mg twice daily) and placebo, with order determined by randomization, and then underwent intravenous methamphetamine challenges (15 and 30 mg). We monitored cardiovascular effects, methamphetamine pharmacokinetics, and reported adverse events. RESULTS:Ibudilast treatment had similar rates of adverse events compared with placebo, and there was no significant augmentation of cardiovascular effects of methamphetamine. Pharmacokinetic analysis revealed no clinically significant change in maximum concentration or half-life of methamphetamine with ibudilast. CONCLUSIONS:Methamphetamine administration during ibudilast treatment was well tolerated without additive cardiovascular effects or serious adverse events, providing initial safety data to pursue ibudilast's effectiveness for the treatment of methamphetamine dependence.
Authors: Marta Sidoryk-Wegrzynowicz; Michal Wegrzynowicz; Eunsook Lee; Aaron B Bowman; Michael Aschner Journal: Toxicol Pathol Date: 2010-11-12 Impact factor: 1.902
Authors: Lucien C D Gibson; Stuart F Hastings; Ian McPhee; Robert A Clayton; Claire E Darroch; Alison Mackenzie; Fiona L Mackenzie; Michiaki Nagasawa; Patricia A Stevens; Simon J Mackenzie Journal: Eur J Pharmacol Date: 2006-03-13 Impact factor: 4.432
Authors: J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant Journal: Neuropsychol Rev Date: 2007-09 Impact factor: 7.444
Authors: G J Wang; L Smith; N D Volkow; F Telang; J Logan; D Tomasi; C T Wong; W Hoffman; M Jayne; N Alia-Klein; P Thanos; J S Fowler Journal: Mol Psychiatry Date: 2011-07-12 Impact factor: 15.992
Authors: Qiu T Ruan; Neema Yazdani; Benjamin C Blum; Jacob A Beierle; Weiwei Lin; Michal A Coelho; Elissa K Fultz; Aidan F Healy; John R Shahin; Amarpreet K Kandola; Kimberly P Luttik; Karen Zheng; Nathaniel J Smith; Justin Cheung; Farzad Mortazavi; Daniel J Apicco; Durairaj Ragu Varman; Sammanda Ramamoorthy; Peter E A Ash; Douglas L Rosene; Andrew Emili; Benjamin Wolozin; Karen K Szumlinski; Camron D Bryant Journal: J Neurosci Date: 2019-11-08 Impact factor: 6.167
Authors: Michael J Li; Marisa S Briones; Keith G Heinzerling; Mariah M Kalmin; Steven J Shoptaw Journal: Drug Alcohol Depend Date: 2019-11-26 Impact factor: 4.492
Authors: Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer Journal: Drug Alcohol Depend Date: 2017-08-31 Impact factor: 4.492
Authors: C Leonardo Jimenez Chavez; Camron D Bryant; Melissa A Munn-Chernoff; Karen K Szumlinski Journal: Int J Mol Sci Date: 2021-05-21 Impact factor: 5.923